MAGEA4 and synovial sarcoma: TCR based engineered cell therapy has shown its potential in cancer and antiviral settings, as underscored by the recent FDA approval of TECELRA (afamitresgne autoleucel), a treatment for advanced MAGE-A4+ synovial sarcoma in adults with particular HLA alleles.